Denmark Markets — Pre-Market Briefing: Novo Nordisk and Genmab Lift the Healthcare Profile (Nov 16, 2026)

The Library Media — Business & Markets · Markets Desk

Denmark Markets — Pre-Market Briefing: Novo Nordisk and Genmab Lift the Healthcare Profile (Nov 16, 2026)

By Clara Ledger

Share

Published November 16, 2026 · 1:26 AM PT · Updated November 17, 2026 · 1:38 PM PT

The Danish benchmark level was not sourced in the supplied market pack, so no Copenhagen index figure is reported. The regional European picture was modestly positive on Monday morning, with the STOXX Europe 600 up 0.09% at 664.76 as of 08:13 GMT, near its record Friday close of 664.14. The benchmark had risen 2.44% over the previous week. Healthcare was among the stronger sectors in Monday’s early European trading, according to the Wall Street Journal, providing relevant context for the advances in Novo Nordisk and Genmab.

Biggest gainers

Novo Nordisk A/S (NOVO.B) 284.50 DKK +2.17% — Weekend news included real-world data showing approximately 6% weight loss after three months for the Wegovy pill, according to Reuters. The pack also cites positive Phase 3 Redefine 9 results for CagriSema and EU approval of FREHEMGO for haemophilia A, reported by Reuters on Friday.

Genmab A/S (GMAB) 3,516.00 DKK +1.97% — Healthcare was among the stronger European sectors on Monday morning. Genmab’s November 5 third-quarter update backed its full-year guidance after three positive Phase III readouts.

Per Aarsleff Holding A/S (PAAL.B) 738.00 DKK +2.36% — No confirmed driver reported for this move.

Biggest losers

FLSmidth & Co. A/S (FLS) 559.50 DKK -1.50% — No confirmed driver reported for this move. The company’s November 11 third-quarter update narrowed its full-year organic-growth guidance to 1–3%, but the pack does not establish that this was the reason for the share decline.

Danske Bank A/S (DANSKE) 370.90 DKK -0.13% — The move was small; no confirmed driver reported for this move.

The supplied Danish movers were led by healthcare names. Novo Nordisk had several identifiable developments in the pack, including the reported real-world Wegovy pill data, CagriSema trial results and European approval for FREHEMGO. Those developments provide relevant company context, although the pack does not quantify the contribution of each item to the share-price advance. Genmab’s rise coincided with broader healthcare strength in Europe and followed a third-quarter update that maintained its full-year guidance after three positive Phase III readouts.

The other listed gainers and decliners had no confirmed session-specific driver. FLSmidth’s recent reduction in its full-year organic-growth guidance is relevant background, but it should not be presented as the established cause of Monday’s decline. Danske Bank’s move was limited.

The broader European session opened near record levels, with the STOXX 600 slightly higher. The regional market continued to show a split between pressure on AI-linked technology names and strength in selected defensive and healthcare sectors. Technology shares fell 1.3% on Friday, while Monday’s early declines included Infineon and Aixtron. Morgan Stanley had upgraded European equities to overweight, and oil’s extended decline was seen as easing inflation and rate-hike concerns.

The week’s outlook includes Nvidia’s earnings and Anthropic’s anticipated listing. Those events may shape sentiment toward AI-linked companies and the wider technology sector, while the early strength in healthcare provides a separate theme in the European market. The supplied pack does not provide a Danish benchmark level, so the share list and regional sector context are the available basis for this briefing.

Clara Ledger
Markets Desk, The Library Media

From The Library — the estate of our family.

Follow Us

X Facebook Instagram Threads Mastodon Bluesky

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top